MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC

ConclusionsOur results reveals that miR-23a-3p may not only serve as a new biomarker for prognosis but also serve as a new therapeutic strategy in the RCC treatment.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research